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Abstract
Background Continuous renal replacement therapy (CRRT)
and intermittent hemodialysis (IHD) offer diverse benefits and
drawbacks for critically ill children with acute kidney injury
(AKI). Sustained low-efficiency daily diafiltration (SLEDD-f)
involves a conceptual and technical hybrid of CRRTand IHD.
We report our SLEDD-f application to critically ill children in
the pediatric intensive care unit (PICU).
Methods SLEDD-f was delivered by the new Fresenius 5008
therapy system with blood flow 5 ml/kg/min, dialysate flow
260 ml/min, hemofiltration 35 ml/kg/h for 8–10 h daily.
Changes in blood pressure, blood gas, electrolyte, hemoglo-
bulin (Hb), and hematocrit (Hct) were closely monitored.
Results From February 2010 to June 2011, 14 critical patients
with a total of 60 SLEDD-f sessions were studied retrospec-
tively. Heparin was used in 46 sessions (76.6%) with no
bleeding complications. Hypertension above 135 mmHg
returned to normal, hypotension below 90 mmHg showed
no drop. Metabolic acidosis and hyperkalemia normalized.
Elevated Hb, Hct, and their ratio revealed improving hemodi-
lution. Three episodes of intradialytic hypotension (5.0%) and
one of circuit clotting (1.7%) led to premature termination.
The 28-day survival rate was 71.4%.
Conclusions This pilot investigation demonstrates that
SLEDD-f provides good hemodynamic tolerance and cor-
rection of fluid overload, pH, and electrolyte imbalance for
critically ill children with AKI.
Keywords Acute kidney injury . Continuous renal
replacement therapy . Intermittent hemodialysis . Sustained
low efficiency daily diafiltration . Critically ill children
Introduction
Two classic options for acute kidney injury (AKI) are intermit-
tent hemodialysis (IHD) and continuous renal replacement
therapies (CRRT), each with benefits and drawbacks. IHD is
applied with the diffusion principle and performed for around
4 h per session every other day. CRRTwith convection only or
combined diffusion is performed nonstop. The superior modal-
ity for AKI in adults remains controversial [1], but CRRT has
seen widest use in children with critical AKI because of con-
tinuous programmed fluid removal plus better hemodynamic
tolerance [2–4]. Yet CRRT frequently gives rise to complica-
tions in such cases: e.g. intradialytic hypotension, hemorrhage,
electrolyte disturbance [5]. The ideal renal replacement for
children should provide adequate hemodynamic stability, good
volume control, solute removal, high efficacy in correcting
acid-base abnormalities, and electrolyte imbalance. It should
involve minimal work with limited cost, be nonlabor-intensive
and/or technically demanding, provide dialysis-free time out of
the pediatric intensive care unit (PICU) for diagnostic and
therapeutic procedures while enhancing renal recovery and
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survival without complications [1, 6]. IHD is not well tolerated
owing to rapid fluid shift and poor quality of life during therapy.
CRRT is better tolerated, yet complications and cost-
effectiveness pose problems, especially in resource-limited
nations [4, 5]. Sustained low-efficiency daily diafiltration
(SLEDD-f), a conceptual and technical hybrid of IHD
and CRRT, is an increasingly popular method of renal
replacement for AKI patients [1, 7]. Adult studies have
yielded excellent clinical and metabolic outcomes in
critically ill AKI patients [7, 8]. To our knowledge, no
one has ever reported on SLEDD-f usage in children;
we thought it worthwhile to share our experience and
rate the clinical efficacy, quality of life, and cost analysis of
SLEDD-f therapy in critically ill children with AKI.
Materials and methods
Patients
The progress records of 14 critical AKI patients fromFebruary
2010 to June 2011 with a total of 60 SLEDD-f sessions in
PICU who met the criteria for RRT were retrospectively
collected and reviewed. Children with body weight (BW) less
than 20 kg, brain death or severe neurological involvement
were excluded. Because of a lack of proper hemodiafilters and
tubing sets for SLEDD-f in children less than 20 kg in Taiwan,
we preferred continuous veno-venous hemofiltration (CVVH)
for them, giving SLEDD-f top priority to larger children and
adolescents. For brain death and severe neurological involve-
ment, palliative care is considered first. We respect family
opinions and suggestions from pediatric neurologists, detail-
ing the advantages and disadvantages of RRT to them.
Data and clinical information included demographic charac-
teristics (age, gender, and body weight), diagnosis, Pediatric
Risk of Mortality III (PRISM III) score, percentage of fluid
overload (%FO), and outcome. Decisions on SLEDD-f were
reached by both the attending intensivist and the nephrologist
according to indications, such as elevated blood urea nitrogen
(BUN) and serum creatinine (sCr), oliguria, acute volume over-
load or electrolyte imbalance refractory to other therapy.
According to ambulatory blood pressure monitoring (ABPM)
and reference values for ABPM in normal children and adoles-
cents in Taiwan [9], we defined systolic blood pressure (sBP)
above 135 mmHg as hypertension and below 90 mmHg as
hypotension. Definitions of AKI and end-stage renal disease
(ESRD) are based on pediatric-modified RIFLE criteria [10].
Multi-organ dysfunction syndrome (MODS) meant that
the underlying primary disease leading to AKI affected
at least one organ system other than the kidneys [11].
The percentage of fluid overload (%FO) was calculated
as fluid in fluid outð Þ ICU admission weightð Þ=  100%
[12]. Technical information regarding SLEDD-f prescription
included blood flow rate, dialysate flow rate, real duration,
replacement fluid, ultrafiltration volume, heparin dose and
complications. Vital signs, blood gas, electrolyte, and biochem-
istry data were closely monitored before, during, and after
SLEDD-f therapy.
To evaluate the changes in inflammatory markers, we
collected serum before and after SLEDD-f. Levels of adi-
ponectin, IL-17A, and IL-6 were measured in duplicate by
ELISA kits (Assay-Pro Inc., Brooklyn, NY, USA), as per the
manufacturer’s instructions.
A questionnaire was specifically designed for ESRD [13],
dialysis [14], and modified quality of life evaluation [15, 16]
and was applied in Taiwan with fair reliability (Cronbach’s α
between approximately 0.888 and 0.924) and validity (Pearson
correlation coefficient between approximately 0.279 and
0.669). We chose the most common complaints from AKI
patients and evaluated their change before and after SLEDD-
f. Chen and Ku [16] found physical symptom distress and
quality of life negatively correlated. Among 25 items of phys-
ical distress, we chose subjective symptoms and perceptions:
appetite, sleep, static activity limitation, chest pain, palpita-
tion, and dyspnea. The first three items had 1–5 score, and the
last three symptoms 1–3, according to the degree of symptom
improvement (a higher score signifying greater improve-
ment). Children had to be conscious and able to answer simple
questions. Rating was based on medical and nursing records.
Components of SLEDD-f
Treatment was performed with a Fresenius 5008 on-line
hemodiafiltration system. Polysulfone high flux hemodiafil-
ter, FX60 (membrane surface 1.4 m2 and priming volume
74 ml) and FX40 (membrane surface 0.6 m2 and priming
volume 32 ml) were used for BW above and below 40 kg
respectively. For operating parameters, blood flow rates
were set at 5 ml/kg/min for BW 20–40 kg or 200 ml/min
for BW above 40 kg, countercurrent dialysate flow to
260 ml/min and filtration rate to 35 ml/kg/h in pre-dilution
mode. According to blood flow (Qb) and filtration rate (Qf),
total pre-dilution replacement fluid was calculated as
Qf  Qbð Þ Qb Qfð Þ=½   60 treatment duration hoursð Þ .
Treatment lasted 8–10 h daily. Constituent concentration of
dialysate and replacement fluid were: [Na+]:138 mEq/L,
[K+]:2.0 mEq/l, [Cl-]:109.5 mEq/l, [Mg2+]:1.0 mEq/l,
[Ca2+]: 3.0 mEq/l, [HCO3
-]:32 mEq/l. Anticoagulation infu-
sion in the extracorporeal blood circuit was unfractionated
heparin with a loading dose of 10–20 IU/kg and maintenance
dose 5–10 IU/kg/h. For those with prolonged activated partial
thromboplastin time (aPTT) >75 s, international normalized
ratio (INR) >2, activated clotting time (ACT) >275 s, platelet
count <50,000/μl, and/or clinical presentation or suspect
bleeding diathesis, we lowered the heparin dose or held it
steady. In most cases, we used aPTT as the parameter and
2302 Pediatr Nephrol (2012) 27:2301–2309
adjusted the heparin dose. We checked aPTT at 0, 3, and 6 h
from the arterial site: if aPTT <35 s or below baseline, heparin
500 IU bolus and add 200 IU/h; if sPTT >35 s, but <45 s, add
heparin 200 IU/h; if aPTT >45 s but <55 s, add heparin
100 IU/h; if aPTT >55 s, but <65 s, keep heparin at mainte-
nance dose; if aPTT >65 s but <75 s, subtract heparin 50 IU/h;
if aPTT >75 s, hold heparin. If any of these parameters (aPTT,
INR, ACT, platelet count) or clinical presentation of bleeding
existed, such as gastric ulcer with bleeding or epistaxis, we held
heparin or adjusted it to the lowest dose. The machine is able to
auto-flush normal saline each hour to prevent tube clotting.
Statistics
All values in figures and tables are expressed as mean ±
standard error. Student’s t tests (unpaired, two-tailed) were
used for intergroup comparison, with p value <0.05 indicat-




FromFebruary 2010 to June 2011, 14 patients received a total of
60 SLEDD-f treatments. Mean age was 14.9±2.3 years, mean
body weight was 54.4±23.3 kg. Average PRISM III scores
were 16.8±23.3. Five patients had PRISM III scores under 10,
another 9 over 10. Table 1 details the clinical characteristics.
Of the 3 ESRD patients, 1 girl with renal transplan-
tation returned to dialysis owing to recurrent focal seg-
mental glomerulosclerosis (FSGS) with progressive
pulmonary edema and intolerance to IHD; 1 girl suf-
fered from progressive generalized edema, hypertension
and intolerance to IHD; and 1 boy with progressive
FSGS to ESRD, cachexia, and intolerance to IHD, but
the peritoneal dialysis tube was not implanted. Intoler-
ance to IHD and poor ultrafiltration were indicators in
these 3 ESRD patients.
Eleven patients had AKI: 2 with renal transplant had
multi-organ dysfunction syndrome (MODS); 1 had a stem
cell transplant with graft-versus-host disease (GVHD) and
MODS; 1 with diabetic ketoacidosis and pulmonary edema;
2 with crescentic glomerulonephritis showed renal damage
progression; 1 with a mediastinal yolk sac tumor suffered
from cardiogenic shock, respiratory failure, and MODS; 1
had lupus nephritis superimposed influenza A infection
complicated by acute respiratory distress syndrome
(ARDS) and MODS; 2 girls with lupus nephritis had refrac-
tory nephrotic syndrome with pulmonary edema; another
girl with lupus nephritis suffered from refractory nephrotic
syndrome and septic shock with Klebsiella pneumonia com-
plicated with MODS.
Thirteen patients had pulmonary edema; 5 had respirato-
ry failure and needed positive airway pressure or intubation
and mechanical ventilation. Six patients diagnosed with













1 Methylmalonic acidemia, renal and liver transplantation,
shock
30 4 3 AKI Yes Yes No
2 Mediastinal yolk sac tumor, cardiogenic shock 22 2 2 AKI Yes Yes Yes
3 Lymphoma, stem cell transplantation, GVHD, shock 26 2 3 AKI Yes Yes No
4 ESRD, renal transplantation, recurrent FSGS 11 3 0 ESRD Yes No Yes
5 ESRD, intolerance to IHD 9 2 0 ESRD Yes No Yes
6 SLE, lupus nephritis, refractory nephrotic syndrome,
intolerance to IHD
9 11 0 AKI Yes No Yes
7 SLE, lupus nephritis, refractory nephrotic syndrome,
Klebsiella pneumonia septic shock
35 3 3 AKI Yes Yes No
8 Diabetic ketoacidosis 10 4 0 AKI Yes No Yes
9 ESRD, renal transplantation, chronic rejection, septic shock 24 4 3 AKI Yes Yes No
10 SLE, lupus nephritis, influenza A infection with acute
respiratory distress syndrome
31 7 1 AKI Yes Yes Yes
11 SLE, lupus nephritis, refractory nephrotic syndrome 4 3 0 AKI Yes No Yes
12 Crescentic glomerulonephritis IgA nephropathy 7 8 0 AKI Yes No Yes
13 Crescentic glomerulonephritis 7 3 0 AKI Yes No Yes
14 FSGS progressing to ESRD, cachexia 10 4 0 ESRD No No Yes
AKI: acute kidney injury; ESRD: end-stage renal disease; FSGS: focal segmental glomerulosclerosis; MODS: multi-organ dysfunction syndrome;
GVHD: graft-versus-host disease; SLE: systemic lupus erythematosus; PRISM: pediatric risk of mortality; IHD: intermitent hemodialysis
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MODS all needed inotropic agents: 4 received three kinds of
inotropic agents and died within 4 weeks.
For 7 critical patients with relative hemodynamic stabil-
ity, sessions of IHD were performed; premature termination
resulted in poor ultrafiltration due to chest tightness, angina,
dizziness, tachycardia, and hypotension. They tolerated
SLEDD-f well, with adequate ultrafiltration, subsiding pul-
monary edema, and few complications. Quality of life
improvements included better sleep, appetite, and static
activity, all without discomfort.
Improvement in blood pressure control
Average treatment duration was 8.0±0.5 h and fluid removal
per treatment was 2,390±103ml. In patients with hypertension,
mean sBP 153.5±9.4 mmHg before SLEDD-f fell to 145.3±
17.2 mmHg (p<0.02) after treatment; on the other hand, for
patients with hypotension, a mean sBP 87.0±3.5 mmHg before
SLEDD-f became 80.9±11.4 mmHg during treatment (p0
0.15; Fig. 1), revealing insignificant depression. Three episodes
of intradialytic hypotension (3 out of 60, 5.0%) led to premature
termination. There was no apparent increase in dose or de novo
institution of inotropic agents during and after treatment.
Improvement of pulmonary edema and pulmonary
hemorrhage
To evaluate correction of hemodilution, we recorded changes
in hemoglobin (Hb), hematocrit (Hct), and their ratio (Hct/
Hb). Before SLEDD-f, mean Hb, Hct, and Hct/Hb ratio were
10.6±1.6 g/dl, 30.5±5.4%, and 2.83±0.15. SLEDD-f
changed these data to 11.6±2.2 g/dl, 33.8±6.0% and 2.95±
0.16 respectively (Fig. 2). A potential trend existed towards
improvement (although not statistically significant), with no
apparent intradialytic hemorrhage or blood consumption.
Pulmonary edema (Fig. 3) improved after SLEDD-f
therapy. A 14-year-old girl with active SLE and refrac-
tory nephrotic syndrome suffered from sudden onset of
cyanosis, dyspnea, and hematemesis. Chest X-ray
revealed a diffuse alveolar pattern, implying alveolar
hemorrhage. SLEDD-f therapy and aggressive immuno-
suppressant treatment resulted in subsidence of pulmo-
nary hemorrhage, and the ventilation and oxygenation
improved gradually.
Improvement of hyperkalemia and metabolic acidosis
Hyperkalemia appeared in 5 patients (mean serum potassi-
um 5.6±0.8 mEq/l before SLEDD-f) and was corrected to
within the normal range (4.3±0.7 mEq/l during and 4.1±
0.7 mEq/l after SLEDD-f, p<0.05). Those with metabolic
acidosis regained normal plasma levels (7.27±0.16 pre-
SLEDD-f and 7.32±0.11 post-SLEDD-f, p<0.05), low
HCO3 returning to within a normal range (20.3±5.7 and
26.5±7.0 mEq/l respectively, p<0.02; Fig. 4). Sodium, cal-
cium, magnesium and/or phosphate showed no significant
change.
Decreased inflammatory markers
We checked the serum inflammatory markers adiponectin,
interleukin 17A (IL-17A), and IL-6 from only 8 survivors.
Before SLEDD-f, serum adiponectin levels were 3,835.0±
1,011.7 pg/ml, IL-17A levels 1,248.2±212.6 pg/ml and IL-6
levels 204.5±100.6 pg/ml. After SLEDD-f, serum adipo-
nectin levels fell significantly to 661.3±377.5 pg/ml (p<
Fig. 1 Changes in blood
pressure (BP) in hypertensive
(systolic BP>145 mmHg) and
hypotensive (systolic
BP<90 mmHg) patients before,
during, and after sustained
low-efficiency daily diafiltra-
tion (SLEDD-f) therapy. Boxes
and bars represent the
interquartile range and the
median value respectively. The
middle number represents the
median value. In a hypotensive
group, the comparison did not
reach statistical significance
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0.001), IL-17A to 10.4±7.6 pg/ml (p<0.001) and IL-6
levels to 61.9±25.7 pg/ml (p<0.001).
Complication during SLEDD-f
Heparin was prescribed in 46 out of 60 treatments (76.6%),
without bleeding complications. In 14 treatments without
heparin, one episode of circuit clotting (1/60, 1.7%) oc-
curred and led to premature termination.
Mortality
Four patients died; 28-day survival was 71.4%. According
to the PRISM III score, 5 patients with PRISM III score <10
had 100% survival; 9 with PRISM III score >10 had 55.6%
survival. Four patients received renal (3 patients) or stem
cell (1 patient) transplantation, and 3 died. A 17-year-old
boy with methylmalonic acidemia (MMA) after liver and
renal transplantation suffered from severe hemorrhagic pep-
tic ulcer with hypovolemic shock, systemic cytomegalovirus
disease, Pneumocystis jiroveci pneumonia with respiratory
failure and hepatorenal syndrome. A 13-year-old girl with
FSGS progressing to ESRD after a renal transplant had an
acute rejection, pneumonia with respiratory failure and sep-
tic shock. The other 17-year-old boy with lymphoma after
stem cell transplantation suffered from graft-versus-host
disease (GVHD), AKI, respiratory failure, and liver failure.
One girl with renal transplantation survived, but returned to
ESRD because of recurrent FSGS and acute rejection. A
14-year-old girl with SLE had refractory nephrotic syn-
drome and died of Klebsiella pneumonia-related septic
shock. These 4 had MODS (Table 1).
Comparison of survivors and nonsurvivors (Table 2)
shows similar age, BW, eGFR, and BUN before SLEDD-f.
Nonsurvivors had a significantly higher PRISM III score,
%FO, MODS, and vasopressor usage. Of 4 nonsurvivors, 1
boy received bone marrow transplantation, another had a
concurrent liver and kidney transplant, while another had a
renal transplant. All had high PRISM III scores, clinical
fluid overload, and MODS.
Analysis of quality of life
In 34 SLEDD-f trials for 6 patients, quality of life analyses
were performed. According to medical charts and nursing
records, sleep quality, appetite, static activity, and objective
symptoms (chest pain or tightness, palpitation, and dyspnea)
scores improved after SLEDD-f (Fig. 5).
Cost analysis
Hemodiafilter and tubing for CVVH costs US$235, versus
about US$69 for SLEDD-f. Because of the longer duration,
CVVH needs larger amounts and more expensive replace-
ment fluid (US$70) than the dialysate needed for SLEDD-f
(US$8). The average cost of each SLEDD-f treatment was
Fig. 2 Changes in
hemodilution before and after
sustained low-efficiency daily
diafiltration (SLEDD-f) thera-
py. Boxes and bars represent
interquartile range and median
value respectively. The middle
number represents the median
value. None of these compari-
sons reached statistical
significance
Fig. 3 Changes in pulmonary edema before and after sustained low-
efficiency daily diafiltration (SLEDD-f) therapy. a Significant lung
marking, blunting costophrenic angle, and cardiomegaly before
SLEDD-f. b Condition improved after SLEDD-f therapy
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US$77 per day, as opposed to CRRT with an average of US
$305. It is hard to calculate personnel fees under a different
nation’s insurance system. Given limited resources, it is
important to select treatments with greater or equal efficacy
and cheaper consumable materials.
Discussion
The present study is the first report of SLEDD-f treatment to
analyze hemodynamic stability, volume control, acid-base,
electrolyte correction, quality of life, and survival in critical
children. SLEDD-f proves to be less costly than CVVH in
the realm of consumable materials. Patients intolerant to
IHD, while treated with SLEDD-f, enjoyed better efficacy,
more stable hemodynamics and better quality of life. Further
comparison will be needed to demonstrate these advantages.
In adults, controversy exists over superior survival after
IHD or CRRT [17]. Differences in clinic, technique, and
distribution of extracellular and intracellular fluid between
populations make it unwise to apply CRRT adult data to
children. Recent studies [2, 18, 19] have suggested CRRT to
be the preferred modality for critical children. Appropriate
CRRT merits special consideration, given the range of body
weight and composition of intra- and extracellular fluid.
Owing to immature renal tubular function, metabolic acido-
sis and electrolyte disturbance develop more readily in chil-
dren than in adults. During CRRT delivery, a substantial
proportion of blood volume was pumped through the extra-
corporeal circuit. Children developed more complications
with CRRT. It is difficult to establish catheterization with
relatively larger caliber central venous or double lumen
catheters; more accurate fluid control is needed, since the
larger extracorporeal volume of the circuit may predispose
to hypotension. In lower body weight patients, extracorpo-
real blood volume exceeds 10% of blood volume, exposing
them to risks associated with hemodynamic instability [4]
and adverse transfusion reaction: anaphylaxis, hemolysis,
infection, lung injury, and GVHD [20].
Two major studies on pediatric CRRT [21, 22] revealed
diffusion-based continuous veno-venous hemodiafiltration
(CVVHDF) and hemodialysis (CVVHD) to be the favored
Fig. 4 Changes in serum
potassium and metabolic
acidosis before and after
sustained low-efficiency daily
diafiltration (SLEDD-f) therapy.
Boxes and bars represent inter-
quartile range and the median
value respectively. The middle
number represents the median
value. Differences between pre-
and post-SLEDD-f therapy were
statistically significant
Table 2 Patients’ characteristics
by survival status
%FO: fluid overload %;






rate given in ml/min/1.73 m2;
BUN: blood urea nitrogen,




Variable All Survival Non-survival p value
n014 n010 n04
Age (years) 14.9±2.3 14.7±2.5 15±2.4 0.426
Weight (kg) 54.4±23.3 57.1±25.9 55.8±17.2 0.463
PRISM at SLEDD-f 16.8±10.6 12±8.2 28.8±4.9 0.0015
%FO before SLEDD-f 4.7±3.0 3.8±2.9 7.1±1.8 0.023
Inotropes (number at SLEDD-f) 1.1±1.4 0.3±0.7 3 <0.001
MODS 42.9% 20% 100% <0.001
eGFR before SLEDD-f 35.2±32.5 33.3±31.6 39.8±39.5 0.375
BUN before SLEDD-f 93.9±66.6 88.2±74.2 108.2±48.2 0.315
Transplantation 4 1 3 0.0045
Shock 4 1 3 <0.001
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modalities (74% and 78%). Better survival was noted
among patients treated with CVVHD and CVVHDF than
among those treated with CVVH [21]. Marshall et al. [7]
showed that SLEDD-f afforded a greater dose of dialysis
than IHD and could provide small solute clearance compa-
rable to that from a CRRT regimen with substitution fluid
rate of 35 ml/kg/h. Based on the theoretical data presented,
increases in either Qf or treatment duration could be easily
induced as part of routine SLEDD-f to afford a similar
amount of convective clearance as CRRT. SLEDD-f is
expected to have better patient outcome and wider clinical
application.
Acute kidney injury is no isolated event, and it engenders
distant organ injury to lungs, heart, liver, and brain via a
mechanism involving neutrophil migration, higher cytokine
concentration, and oxidative stress [23]. Understanding the
mechanism behind AKI-induced distal organ injury is vital,
as it may reveal new therapeutic targets. We found a signif-
icant decrease in serum adiponectin, IL-17A, and IL-6 level
in survivors after SLEDD-f, a phenomenon that might rep-
resent an association between removing certain cytokines
and AKI outcome, but this study is limited in terms of its
small number and retrospective design.
Adiponectin, an adipokine, is produced almost exclusive-
ly by adipocytes and circulates in high concentrations in
human plasma [24, 25]. Alteration in blood adiponectin
concentrations has been linked to many human diseases
in numerous cross-sectional and prospective studies.
Adiponectin is markedly increased in patients with ne-
phrotic syndrome; proteinuria is strongly related to circulating
adiponectin in patients with nephrotic syndrome and non-
nephrotic renal disease [26]. Investigation of critical illness
[25] revealed an inverse correlation between adiponectin and
inflammatory cytokines; whether this emanates from the dis-
ease process itself, or whether patients with lower levels of
this hormone are more susceptible to critical illness is un-
known. However, there were no data on the association
among adiponection, AKI, diafiltration, and prognosis. Our
study revealed decreased adiponectin levels after SLEDD-f in
8 survivors. The phenomenon might imply either SLEDD-f
removal of adiponectin or represent a natural recovery from a
critical condition. This limited retrospective study had neither
control nor comparative groups; in future we aim to conduct
better-designed research to investigate these possibilities.
IL-17A is a proinflammatory cytokine released by both T
cells and innate immune cells, and plays a key role in both
innate and adaptive immunity [27]. Convincing experimen-
tal evidence indicates that IL-17-producing T cells contrib-
ute to kidney injury in renal inflammatory diseases [28, 29].
In animal studies after ischemic or non-ischemic AKI, plas-
ma TNF-α, IL-17A, and IL-6 increased sharply, leading to
small intestine and liver injury [30]. In critically ill patients,
controversial results revealed that IL-17 might induce mul-
tiple organ dysfunctions [31–33]. In our study, high serum
IL-17A decreased significantly after successful SLEDD-f
treatment in 8 survivors. Changes in serum adiponectin,
IL-17A, and IL-6 might indicate that SLEDD-f is able to
remove certain inflammatory markers. However, incomplete
data on the clearance of urea and creatinine limited the
possibility of rating the efficacy of SLEDD-f in terms of
depuration. Further research is needed in this area.
Pulmonary edema, acid-base disturbance and/or electro-
lyte imbalance were principal indications for renal replace-
ment therapy. IHD is the most efficient modality for fluid,
metabolic, and electrolyte control. Yet rapid fluid shifts are
not well tolerated in complicated and unstable clinical con-
ditions [4]. Such patients better tolerate CRRT hemodynam-
ically; hemorrhage and/or electrolyte disturbance represent
major complications [5]. Our 3 pulmonary edema patients
who were intolerant to IHD adapted to SLEDD-f well,
showing improved symptoms and quality of life.
Children tend to bleed more than adults [34, 35] during
maturation of the hemostatic system. According to the liter-
ature regarding the complications of CRRT in critically ill
children [5], 10% on CRRT presented clinically significant
hemorrhage, with no correlation between the presence of
hemorrhage and age, weight, diagnosis or clinical severity at
the start of CRRT. Though differences did not reach statis-
tical significance, they indicated higher mortality in patients
with rather than without hemorrhage. Heparin use requires
careful adjustment to avoid either hemorrhage or circuit
clotting. Hemorrhage in critically ill children with CRRT
could arise from a number of factors: coagulation disorder,
platelet dysfunction, altered tissue perfusion, CRRT itself,
and anticoagulation. When our SLEDD-f patients had any
clinical presentation of bleeding or suspected hemorrhagic
diathesis, heparin was adjusted or held. No such bleeding
complication appeared in our patients, but one episode of
Fig. 5 Changes in quality of life before and after sustained low-efficiency
daily diafiltration (SLEDD-f) therapy. Asterisk represents p<0.05
Pediatr Nephrol (2012) 27:2301–2309 2307
circuit clotting occurred at 3.5 h and led to premature
termination in a patient with multi-organ involvement.
Hypotension is a key problem for critically ill children.
Hypotension at CRRT connection is one of the most com-
mon CRRT-related complications [5]. After smooth connec-
tion, CRRT is advantageous for hemodynamically unstable
patients as it need not be terminated because of hypotension,
unlike IHD. All our patients had smooth connection, while
three episodes of intra-dialytic hypotension occurred in shock
cases. We tried our best to slow down blood flow, raise the
inotropic dose, and cease ultrafiltration, yet slower blood flow,
disseminated intravascular coagulation (DIC), and thrombosis
resulted in tube clotting and discontinuation of therapy. The
need to terminate therapy depended on RRT modality effects
as well as clinical conditions. This is also common for CVVH,
especially for unstable hemodynamic patients, in our experi-
ence. The small number of patients precluded us from deter-
mining the superiority of either SLEDD-f or CVVH.
Mortality in critically ill children requiring CRRT is
reported to be between 35.6 and 57.0% [21, 22, 36–38].
Different diseases and demographic traits correlate with
diverse mortality rates. In adults on CRRT, risk factors
associated with mortality were age, greater clinical severity
score, hemodynamics, sepsis, and respiratory failure. In a
prior study by Symons et al., mortality rose with lower body
weight (<10 kg), younger age (<1 year), higher PRISM II
score (>10), combined fluid overload, metabolic acidosis,
and multi-organ involvement [22]. In the prospective pedi-
atric continuous renal replacement therapy (ppCRRT) reg-
istry group, survival of patients with PRISM II score <10
was 55%; for those with >10, 47% [22]. In our report of
those treated with SLEDD-f, the percentages were 100%
and 55.6% in patients with PRISM III score <10 and >10
respectively. Besides PRISM III score, other parameters,
such as pre-RRT multiple organ failure, fluid overload,
hemodynamic disturbance, and administration of cardioac-
tive drugs can offer more reliable prognostic indicators.
Further analysis of critically ill children with MODS receiv-
ing CRRT in the ppCRRT registry group [11] highlighted
the PRISM score, central venous pressure (CVP), and the
percentage of fluid overload (%FO) at CRRT initiation as
being sharply lower for survivors versus nonsurvivors.
Table 2 compares surviving and nonsurviving patients: non-
survivors more frequently suffered from MODS and had
higher PRISM scores, %FO at ICU, and inotropic agent
usage before SLEDD-f initiation. Patients requiring
SLEDD-f for primary or predominant renal disease tallied
lower PRISM scores and had 100% survival. Early SLEDD-
f intervention before severity progresses and fluid overload
increases may improve the patient survival rate and decrease
morbidity. In ppCRRT [22], the survival rate in liver disease
and/or transplant patients was lower than the overall rates.
Among nonsurviving patients, 2 with renal and 1 with stem
cell transplant suffered from shock and MODS, including
respiratory failure, AKI, and liver failure. Transplantation
and shock predisposed to a poor prognosis.
This report is limited by its retrospective design, small
patient numbers, lack of control groups for diverse treat-
ments, and the fact that there were no young patients weigh-
ing less than 20 kg, who are usually reported to be at a
higher risk of complications and death. With respect to
quality of life, a further limitation was the fact that it was
based on a retrospective review of medical and nursing
records, not an ad-hoc questionnaire.
In conclusion, our pilot study showed that the advantages
of SLEDD-f for critically ill children with renal injury
included good hemodynamic tolerance, stable BP, well con-
trolled fluid overload, good correction of fluid overload,
acidosis, and electrolyte imbalance, lower cost, and good
survival. These results need confirmation in a wider study
comparing RRT modalities in such children.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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